Given the frequency and consistency with which these autoimmune adverse effects appear, many physicians advocate screening all patients treated with anti-CTLA-4 agents for endocrinopathies with measurements of morning serum cortisol level, electrolytes (to detect hyponatremia or hyperkalemia as indicators of adrenalitis), TSH, and free T4 levels. The gene discussed is CTLA4; the disease is Hyponatremia.